We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
India's Cipla sets sights on Avastin, Herceptin and Enbrel.
- Authors
Jayaraman, Killugudi
- Abstract
The article reports on the venture of India-based generic manufacturer Cipla into biosimilars in 2010 with particular interest in Avastin bevacizumab, Herceptin trastuzumab and Enbrel etanercept. Cipla has invested in BioMab of China and MabPharm to fill the void in its lack of biologics expertise. A total of 10 monoclonal antibody (mAb) drugs are targeted by the Cipla-China partnership. Also identified are keys to success of a biosimilar in the global market including safety and efficacy.
- Subjects
CIPLA Ltd.; BEVACIZUMAB; TRASTUZUMAB; ETANERCEPT; BIOMAB Pharmaceuticals (Company); MABPHARM Pvt. Ltd.; MONOCLONAL antibodies; THERAPEUTICS
- Publication
Nature Biotechnology, 2010, Vol 28, Issue 9, p883
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0910-883a